Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 16/20 | 0.81 |
| ▸ | CNR1 | P21554 | 1/20 | 0.81 |
| ▸ | ACHE | P22303 | 1/20 | 0.81 |
| ▸ | PDE4A | P27815 | 1/20 | 0.81 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.81 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.81 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.81 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.81 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | PCSK9 | Q8NBP7 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mk-3168 SCHEMBL5529333 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL19159931 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL5534755 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL2681300 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 C-11 SCHEMBL30531781 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL2681510 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL6954837 | 0.90 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL5531395 | 0.84 | FAAH (0.90) | FAAHCNR1ACHEPDE4APDE4B | |
| Mk-3168 SCHEMBL5529344 | 0.83 | FAAH (1.00) | FAAHCNR1ACHEPDE4APDE4B | |
| SCHEMBL7909520 | 0.82 | FAAH (0.83) | FAAHCNR1ACHEPDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | QUEST VENTURES LTD. (GB) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150346-A1 | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome | FAAH, FAAH2, MGLL | FAAH 1/4885CNR1 73/4885ACHE 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.